Accelero Biostructures

Accelero Biostructures is a United States-based structural biology and drug discovery services company headquartered in San Francisco, California. Founded in 2015, the company provides high-throughput protein X-ray crystallography-driven drug discovery and structural biology solutions to pharmaceutical and biotechnology companies. Its work is organized around two proprietary service platforms, ABS-Services℠ and ABS-OneStep℠, which together cover the gene-to-structure process — from target gene to solved protein crystal structure — for structure-based drug discovery programs. The company's scientific foundation draws on more than 15 years of high-throughput protein X-ray crystal structure determination carried out at the Joint Center for Structural Genomics (JCSG) consortium, which was headed by Ian Wilson. The JCSG brought together The Scripps Research Institute in La Jolla, the Genomics Institute of the Novartis Research Foundation in La Jolla, Sanford Burnham Prebys Medical Discovery Institute in La Jolla, and SLAC National Accelerator Laboratory in Menlo Park. Funded through the National Institutes of Health–National Institute of General Medical Sciences' Protein Structure Initiative and through investments from participating institutions, the JCSG developed a robust gene-to-structure pipeline operated in an industry-like, multi-institutional manner, with efficiency and cost as primary drivers. More than 1,500 novel protein structures were solved through that effort, resulting in over 300 publications. Accelero positions itself as a partner to both established and emerging pharmaceutical and biotechnology companies. Its stated areas of focus include structural biology for biologics and biotechnology, fragment-based and structure-based drug discovery and structural biology for pharma and academia, and bioinformatics and computational biology for structure-based drug discovery and structural biology. The company emphasizes continuous innovation to remain best in class in high-throughput protein crystallography. The name "Accelero" reflects the company's mission to accelerate drug discovery and also references the accelerator component of synchrotrons — extremely brilliant X-ray light sources used to collect X-ray diffraction data for solving protein crystal structures. The company's branding incorporates a slanted view of a synchrotron rendered in a central California Gold color, representing both the brilliance of a synchrotron light source and the company's home state of California, with its history from the California gold rush to its role as the birthplace of biotechnology. As a private services company, Accelero operates primarily as a business-to-business scientific partner rather than as a consumer-facing brand. Its clients are pharmaceutical and biotechnology organizations that need structural biology expertise and high-throughput crystallography capacity to support structure-based drug design, fragment-based discovery, and biologics programs.

Accelero Biostructures was founded in 2015 and is headquartered in San Francisco, California, United States. From its inception, the company has focused on providing state-of-the-art, high-throughput protein X-ray crystallography-driven drug discovery and structural biology solutions to pharmaceutical and biotechnology companies through its ABS-Services℠ and ABS-OneStep℠ platforms. The scientific lineage of the company traces to the Joint Center for Structural Genomics (JCSG) consortium, which was headed by Ian Wilson. The JCSG comprised The Scripps Research Institute in La Jolla, the Genomics Institute of the Novartis Research Foundation in La Jolla, Sanford Burnham Prebys Medical Discovery Institute in La Jolla, and SLAC National Accelerator Laboratory in Menlo Park. It was funded through the National Institutes of Health–National Institute of General Medical Sciences' Protein Structure Initiative and through considerable investments from participating institutions. The consortium developed a robust gene-to-structure pipeline with a multi-institutional, industry-like operation, driven primarily by efficiency and cost. More than 1,500 novel protein structures were solved through the JCSG effort, resulting in over 300 publications. Accelero capitalizes on more than 15 years of this high-throughput protein X-ray crystal structure determination work. The company's name reflects its mission to accelerate drug discovery and also references the accelerator component of synchrotrons, the extremely brilliant X-ray light sources used to collect X-ray diffraction data for solving protein crystal structures. Its visual identity incorporates a slanted view of a synchrotron in a central California Gold color, representing both the brilliance of a synchrotron light source and the company's home state of California, with its pioneering history from the California gold rush to its status as the birthplace of biotechnology. Accelero describes a track record of over 20 years and states that it continuously builds and innovates to remain best in class. Its areas of focus span structural biology for biologics and biotechnology; fragment-based and structure-based drug discovery and structural biology for pharma and academia; and bioinformatics and computational biology for structure-based drug discovery and structural biology. The company partners with both established and emerging pharmaceutical and biotechnology companies.

• 2015

  Accelero Biostructures is founded and begins providing high-throughput protein X-ray crystallography-driven drug discovery and structural biology services.

• The company builds its service offering around the ABS-Services℠ and ABS-OneStep℠ platforms.

• Accelero capitalizes on more than 15 years of high-throughput protein X-ray crystal structure determination from the JCSG consortium, which solved more than 1,500 novel protein structures and produced over 300 publications.

A specialist contract research partner providing high-throughput protein X-ray crystallography and structural biology services to pharmaceutical and biotechnology companies, positioned on a proven gene-to-structure pipeline and more than 20 years of scientific track record.

• ABS-Services℠

  A protein crystallography service platform for structure-based drug discovery and structural biology.

• ABS-OneStep℠

  A protein crystallography-driven drug discovery platform covering the gene-to-structure process.

1. 1Accelero Bio Structures — Homeaccelerobio.com
2. 2About Us — Accelero Bio Structuresaccelerobio.com
3. 3Accelero Biostructures — Wikidatawikidata.org